ICU Medical (NASDAQ:ICUI) Reaches New 12-Month High at $186.00

ICU Medical, Inc. (NASDAQ:ICUI) reached a new 52-week high during trading on Monday . The stock traded as high as $186.00 and last traded at $184.71, with a volume of 24431 shares trading hands. The stock had previously closed at $174.47.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ICUI shares. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a report on Thursday, August 8th. KeyCorp increased their target price on ICU Medical from $136.00 to $147.00 and gave the company an “overweight” rating in a research report on Thursday, August 8th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Thursday, September 12th. Finally, Raymond James raised their price target on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $149.00.

ICU Medical Stock Performance

The firm has a 50 day moving average price of $154.77 and a 200 day moving average price of $124.17. The stock has a market cap of $4.53 billion, a PE ratio of -76.40 and a beta of 0.65. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.56. The company had revenue of $596.50 million for the quarter, compared to the consensus estimate of $556.64 million. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter last year, the company earned $1.58 earnings per share. As a group, research analysts forecast that ICU Medical, Inc. will post 3.76 earnings per share for the current year.

Insiders Place Their Bets

In related news, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $163.22, for a total transaction of $408,376.44. Following the completion of the sale, the vice president now owns 13,107 shares of the company’s stock, valued at $2,139,324.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $163.22, for a total transaction of $408,376.44. Following the completion of the sale, the vice president now owns 13,107 shares of the company’s stock, valued at $2,139,324.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $156.04, for a total value of $1,872,480.00. Following the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $16,320,691.72. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,552 shares of company stock valued at $4,537,802. 6.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Scout Investments Inc. raised its position in ICU Medical by 16.3% during the first quarter. Scout Investments Inc. now owns 51,819 shares of the medical instruments supplier’s stock valued at $5,463,000 after acquiring an additional 7,272 shares in the last quarter. Wakefield Asset Management LLLP purchased a new stake in shares of ICU Medical in the first quarter valued at approximately $989,000. Vanguard Group Inc. increased its position in shares of ICU Medical by 14.8% in the fourth quarter. Vanguard Group Inc. now owns 2,440,729 shares of the medical instruments supplier’s stock valued at $243,438,000 after buying an additional 315,103 shares in the last quarter. SG Americas Securities LLC increased its position in shares of ICU Medical by 441.7% in the second quarter. SG Americas Securities LLC now owns 5,818 shares of the medical instruments supplier’s stock valued at $691,000 after buying an additional 4,744 shares in the last quarter. Finally, Sei Investments Co. increased its position in shares of ICU Medical by 52.1% in the first quarter. Sei Investments Co. now owns 28,586 shares of the medical instruments supplier’s stock valued at $3,068,000 after buying an additional 9,793 shares in the last quarter. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.